Rimonabant also known as Acomplia is a prescription based anti-obesity drug. Its main purpose is reduction in appetite in order to fight obesity. Rimonabant is the foremost selective CB1 receptor obstructer to be approved for use all over the world. In Europe, it is recommended for consumption in combination with diet and exercise for patients with a body mass index (BMI) greater than 30 kg/m², or patients with a BMI greater than 27 kg/m² with linked risk factors like type 2 diabetes or dyslipidaemia. In the UK, it has been made available for sale since the end of July 2006. As of 2008, the drug is available worldwide in more than 56 countries.

On 21 June 2006, the European Commission approved the sale of Acomplia in the then 25-member European Union. Sanofi proclaimed that the first country in which Acomplia will be sold is the United Kingdom. Sales commenced in July 2006. Sanofi also said that it expects that the drug will be sold soon afterward in Denmark, Ireland, Germany, Finland and Norway. It is also anticipated to be sold in Belgium and Sweden from the year 2007. Normal degree of obesity will, according to official medical recommendations would not be adequate to get the prescription in Sweden; for it there are added requirements pertaining to abnormal blood lipid levels.

The EU's approval was not a blanket approval; neither did it approved Acomplia for problems which are not related to obesity like smoking cessation, although unofficial usage of the drug is still possible. The approval is in conjunction of diet and exercise for the treatment of obese patients that is people who have BMI index greater than or equal to 30, or overweight patients (BMI greater than 27) with connected risk factors, such as type 2 diabetes.

Acomplia Rimonabant works by hindering the CB-1 receptors which are responsible for formulating food intake of the body. When these receptors are blocked, the natural appetite of the body reduces. As a result you feel satisfied even with consumption of lesser amounts of food. In this manner, acomplia facilitates loss on extra weight from your body.

It has also been observed that Acomplia is effective in assisting some habitual smokers to quit smoking. Sanofi-Aventis is presently conducting studies to find out the possible value of rimonabant in smoking-cessation therapy. The Studies with acomplia and Tobacco Use (STRATUS) Program involves as many as 6,000 participants. STRATUS is intended to explore not only one but two smoking-related therapies: first, to use rimonabant directly to support in smoking cessation; second, to help avert weight gain in former smokers. Apparently preliminary results propose that rimonabant is effectual for both uses. However, the FDA has clearly affirmed to Sanofi-Aventis that in the absence of any additional studies acomplia cannot be approved in the United States for smoking cessation therapy.